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ABSTRACT 
BEAR (Binding Estimation After Refinement) is a computational method for structure-based virtual screening. It was 
set up as a post-docking processing tool for the refinement of ligand binding modes predicted by molecular docking 
programs and the accurate evaluation of free energies of binding. BEAR has been validated in a number of computa- 
tional drug discovery applications. It performed well in discriminating active ligands with respect to molecular decoys 
of biological targets belonging to different protein families as well as in discovering biologically active hits. Recently, it 
has also been validated in the emerging field of G-protein coupled receptors structure based virtual screening. 
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1. Introduction 
Early stage drug discovery aims at identifying new active 
compounds against biological targets involved in a given 
pathology. A widely used method for the discovery of 
biologically-active hits is High-Throughput Screening 
(HTS). However, the high costs and relatively low hit 
rates of HTS make computational tools for drug design 
an attractive and straightforward alternative [1]. Notably, 
virtual screening represents an efficient computational 
approach for the inexpensive and efficient assessment of 
large libraries of small molecules [2]. When structural 
information for a target of interest is available, Structure- 
Based Virtual Screening (SBVS) techniques such as mo- 
lecular docking may be applied [3,4]. Molecular docking 
programs focus on the prediction of suitable binding 
modes for small molecules in the binding site of the se- 
lected target and the subsequent scoring for the assess- 
ment of the binding strength [5]. Despite some valuable 
improvements in the accuracy and efficiency of the algo- 
rithms used for molecular docking, there are still consid- 
erable drawbacks and limitations to face [3,6]. Among 
these, a major hurdle to overcome is the reliable simula- 
tion of the flexibility of both ligands and receptor, which 
play a central role in molecular interaction establishment 
and binding strength. Furthermore, different scoring 
functions have been implemented in currently used mo- 
lecular docking programs, but obtaining a fair correlation 
between docking scores and experimental activity data 
remains a difficult task. These limitations are responsible 
for the occurrence of false-positive and false-negative 
hits in the ranked lists resulting from the screenings per- 
formed with standard docking methods. Hence, it is a 
general opinion that molecular docking results may be 
improved by post-processing with more accurate tools, 
gaining higher accuracy in both binding modes predic- 
tion and energy scoring. 
For this purpose, we developed Binding Estimation 
After Refinement (BEAR) [7], an automated post-dock- 
ing tool consisting of a conformational refinement of 
docking binding modes with molecular dynamics fol- 
lowed by a prediction of binding free energy performed 
with MM-PBSA and MM-GBSA algorithms [8-12]. Re- 
cently, BEAR has been validated and applied in a num- 
ber of drug discovery applications. In this review we will 
give an overview of the BEAR workflow and the results 
obtained so far. 
2. The BEAR Workflow 
The BEAR program consists of an initial pre-processing 
step followed by an automated three steps procedure for 
structural refinement of the ligand-receptor complexes. 
Then, a final step is made for computing the binding free 
energy of the ligand in the refined complex. The proce- *Corresponding author. 
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dure is iterative and able to automatically screen com- 
pounds in a database. The workflow is graphically rep- 
resented in Figure 1. We implemented for these purposes 
modules available in the AMBER suite (Leap, Ante- 
chamber, Sander, pbsa) [13,14]. 
During the pre-processing step, hydrogen atoms are 
added to the receptor, atomic charges (AM1-BCC) are 
calculated for the small molecules, missing force-field 
parameters are assigned with parmcheck, and topologies 
are built for the ligand, receptor and the complex. Then, 
the following iterative three steps procedure is based on 
Molecular Mechanics (MM) and Molecular Dynamics 
(MD) cycles. In particular, an initial MM energy mini- 
mization of the whole protein-ligand complex is per- 
formed, followed by a short MD simulation where the 
ligand is allowed to move, and a final re-minimization of 
the entire complex. Finally, the binding free energy of 
the refined complexes is calculated by MM-PBSA and 
MM-GBSA methods. Further details about energy mini- 
mization, MD, and binding free energy calculations can 
be found in reference [7]. 
3. Validation Studies 
BEAR has been extensively validated as a useful tool for 
post-processing molecular docking results in different 
case studies [7,15-19]. In these works, proteins spanning 
different classes have been selected as targets. In general, 
BEAR proved to be able to predict free energies of bind- 
ing that correlate with experimental activities and to rec-  
ognize true actives seeded within larger datasets of mo- 
lecular decoys. 
3.1. Aldose Reductase 
As a first attempt to set up and validate BEAR, the work- 
flow was applied to a series of aldose reductase inhibitors 
[15]. In particular, 28 inhibitors spanning five orders of 
magnitude of biological activity and characterized by 
significant chemical diversity were selected. Their bind- 
ing modes were taken from the available X-ray crystal 
structures. Then, the combined MM/MD protocol fol- 
lowed by binding free energy scoring was applied and 
tested for the ability to score the ligands in agreement 
with their known biological activity. The results obtained 
in such a challenging task showed good correlations (r2 = 
0.80 by MM-PBSA, r2 = 0.73 by MM-GBSA) between 
computed and experimental free energies of binding. 
This was a first important indication that our refinement 
and rescoring method was able to provide results in sig- 
nificant agreement with experiment. It can be applied for 
an accurate rescoring of structurally unrelated molecules 
in a given binding site, and the computational times 
needed to refine and rescore the docked complexes are 
compatible with virtual screenings. 
3.2. Pf-DHFR 
Three independent studies tested the ability of BEAR to 
recognize Plasodium falciparium dihydrofolate reduc- 
tase (Pf-DHFR) active molecules from larger datasets of  
 
 
Figure 1. The BEAR workflow. 
Copyright © 2013 SciRes.                                                                                 CMB 
A. ANIGHORO, G. RASTELLI 29
 
molecular decoys or molecules without known activities 
for this target [7,16,17]. 
In the first study, BEAR was able to significantly en- 
rich 14 known ligands seeded into the National Cancer 
Institute (NCI) diversity database [20], containing 1720 
compounds with unknown activities on Pf-DHFR [7]. 
The BEAR performance was clearly superior with re- 
spect to that of the docking method used, i.e. AutoDock 
[21]. In the second case, BEAR performance was evalu- 
ated using 201 known ligands and 7150 decoys contained 
in the DHFR data set taken from the directory of useful 
decoys (DUD) [16,22]. In the third case, the same 201 
known ligands were seeded in 1.5 million compounds 
contained at that time in the lead-like subset of the ZINC 
database [17,23]. Here, the objective was to test the abil- 
ity of BEAR to discriminate a very limited number of 
true binders from a very large set (1.5 million) of com- 
pounds, a situation typical of virtual screening cam- 
paigns. The results obtained after docking and BEAR 
post-processing were compared by analysing the enrich-
ment factors. In all three cases, including the more chal-
lenging one, BEAR was able to perform strikingly better 
compared to standard docking. Therefore, BEAR per-
formed well in virtual screenings against a biological 
target with known structure and different database of 
compounds. In this regard, BEAR demonstrated to be a 
reliable computational tool to be implemented in drug 
discovery. 
3.3. Estrogen Receptor, Thymidine Kinase,  
Factor Xa, Adenosine Deaminase, Aldose  
Reductase, and Enoyl ACP Reductase 
In a later investigation, we tested the performance of 
BEAR on several targets with different binding sites, 
using both a single and a multiple conformation approach. 
The use of a collection of multiple protein conformations 
is considered a valuable approach to account for protein 
flexibility in virtual screenings. This procedure is usually 
referred to as ensemble docking. Recently, BEAR has 
been applied for post-processing docking results of six 
targets spanning different protein families, namely, es- 
trogen receptor, thymidine kinase, factor Xa, adenosine 
deaminase, aldose reductase, and enoyl ACP reductase 
[18]. In this work, we used two docking programs, Lib- 
Dock [24] and Autodock, and multiple conformations for 
each target. 
Enrichment factor plots were built for each target and 
the percentage of known inhibitors, taken from the DUD 
data set, retrieved at different early stages of the ranked 
databases were annotated. A comparative analysis of the 
enrichment factors showed that the scoring functions 
implemented in BEAR are generally able to yield higher 
enrichments of known ligands compared to the standard 
docking scoring functions. However, rather poor enrich- 
ments of known ligands have been obtained with both  
docking and BEAR in case of particularly challenging 
targets for docking studies, such as adenosine deaminase 
and enoyl ACP reductase. This was mainly due to diffi- 
culties in retrieving correct binding modes for these tar- 
gets. 
The use of multiple protein conformations combined 
with the application of BEAR showed potential benefits 
in virtual screening context yielding to higher enrichment 
factors. Nevertheless, different strategies may be imple- 
mented for the compound selection (best scoring docking 
solution within multiple structures, top scoring com- 
pounds in each structure). 
3.4. G-Protein Coupled Receptors 
Recently, we have applied BEAR to G-protein coupled 
receptors (GPCRs) SBVS [19]. These proteins are highly 
relevant targets for drug discovery, and advances in 
GPCRs structural determina- tion by X-ray crystallogra-
phy are opening unprecedented opportunities to discover 
new biologically active hits using SBVS [25]. Therefore, 
we wanted to test BEAR on GPCRs with known crystal 
structure. 
In our work, four GPCRs have been studied, namely 
β2-adrenergic (β2), adenosine A2a (A2a), dopamine D3 
(D3), and histamine H1 (H1). Receptor flexibility and in- 
duced fit are known to play a major role in the binding 
and potency of their antagonists, hence it was investi- 
gated whether a structural refinement of the docking 
complexes with molecular dynamics could be particu- 
larly useful. Furthermore, we hypothesized that a more 
accurate description of desolvation free energies per- 
formed by MM-PBSA could improve the binding affinity 
predictions of the many protonated biogenic amines 
found among the known antagonists. 
For each of the four targets analysed, the ability to rec-
ognize a small number of known antagonists (between 20 
and 56) in a database of 1000 drug-like decoys have been 
assessed through the analysis of enrichment factor plots 
and binding modes assessment. In most cases, BEAR 
gave better performances compared to the docking pro- 
gram used, i.e. AutoDock. A strikingly better perform- 
ance was obtained in the case of the β2-adrenergic recep- 
tor, where AutoDock gave enrichment factors close to 
random while BEAR significantly enriched the hit list 
with active antagonists. Moreover, we showed that the 
results could be improved for the A2a receptor by using a 
suitable combination of structural waters that participate 
in hydrogen bonding network with the antagonists. Fi- 
nally, for the first time, BEAR’s implications on multi- 
target drug screening were put forward. In particular, we 
found that five known antagonists in common between 
the H1 and D3 receptors were scored and ranked favoura- 
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bly in each of the two target screenings. The rational de- 
sign of multi-target (polypharmacology) ligands is be-
coming increasingly important in drug discovery [26], 
and our results suggest that BEAR may be useful in dis-
covering multi-target hits shared by different GPCRs. 
3.5. Plasmepsin II 
Plasmepsin II, an aspartic protease with a key role in the 
metabolism of Plasmodium falciparum, is a validated 
target in the therapy of malaria. In a recent successful 
virtual screening campaign, BEAR was applied for the 
discovery of new Plasmepsin inhibitors [27]. 
In this work, 5000 top-scoring compounds obtained 
from a previous docking screening [28] conducted with 
FlexX [29] have been selected and post-processed with 
BEAR. The post-processed compounds have been ranked 
according to the estimated free energy of binding and the 
top fraction of the ranked lists has been analysed and 
then biologically tested on the purified protein. Among 
the best energy scoring compounds BEAR identified four 
promising chemical classes, namely N-alkoxyamidines, 
guanidines, amides, and ureas and thioureas. Visual in-
spection of the binding modes of the top-ranking deriva-
tives belonging to these four classes confirmed that these 
molecules were able to establish key interactions with the 
receptor binding site. After this filtering, thirty best- 
scoring compounds were selected as representatives of 
the four classes and then biologically tested on the puri-
fied protein. Remarkably, 26 compounds out of the 30 
tested showed IC50 values ranging from 4.3 nM to 1.8 
μM. This was a fairly exceptional hit rate for a virtual 
screening. 
4. Final Remarks 
Our studies have shown that BEAR performed well in a 
number of validation studies conducted on proteins of 
different families and ligands and databases of different 
nature. Moreover, we have shown the potential of BEAR 
in both single and multiple receptor conformation ap-
proaches as well as its utility in screening transmembrane 
GPCRs. Finally, we provided the first evidence that 
BEAR may be suited to recognize multi-target active 
compounds. Using BEAR, biologically active compounds 
were discovered with a very good hit rate. 
All these evidence testifies that BEAR is a useful and 
reliable computational tool to be implemented in struc-
ture-based virtual screenings. 
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